文献速递神经核医学心脏核医学

分子影像方法预测轻度认知障碍向痴呆进展的诊断性能:一项更新的系统综述

Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-15

本更新系统综述汇总2017—2022年分子影像(淀粉样蛋白、tau、[18F]FDG-PET、DaT-SPECT及心脏[123I]-MIBG显像)预测轻度认知障碍向痴呆进展的诊断准确性研究,按PRISMA方法筛选并用QUADAS-2评价。预测向痴呆(主要为阿尔茨海默痴呆)进展的敏感度和特异度:[18F]FDG-PET为43-100%和63-94%,淀粉样蛋白PET为64-94%和48-93%。结论认为分子影像对MCI向阿尔茨海默痴呆进展的预测具有中等至良好准确性,非AD疾病的纵向研究稀少。

要点

  • [18F]FDG-PET预测MCI向痴呆进展的敏感度43-100%、特异度63-94%,淀粉样蛋白PET分别为64-94%、48-93%。
  • DaT-SPECT鉴别路易体病与非路易体病敏感度47-100%、特异度71-100%。
  • 非AD疾病及tau-PET、DaT-SPECT、[123I]-MIBG显像缺乏纵向研究,准确性数据来自小样本横断面研究。

核心结论

  • 分子影像在预测MCI向阿尔茨海默痴呆进展方面具有中等至良好准确性。
  • 非AD疾病的纵向研究稀少,这些领域需要额外努力。

研究设计与样本

  • 更新系统综述,检索2017—2022年文献,按PRISMA方法筛选,用QUADAS-2工具评价。
  • 纳入标准:MCI受试者≥50例、随访≥3年、金标准为进展为痴呆或病理诊断、报告前瞻性准确性指标。

主要发现

  • [18F]FDG-PET预测向痴呆(主要为阿尔茨海默痴呆)进展的敏感度43-100%、特异度63-94%。
  • 淀粉样蛋白PET预测向痴呆(主要为阿尔茨海默痴呆)进展的敏感度64-94%、特异度48-93%。
  • DaT-SPECT鉴别路易体病与非路易体病的敏感度47-100%、特异度71-100%。
  • tau-PET鉴别路易体痴呆与后皮质萎缩的敏感度88%、特异度100%。
  • [123I]-MIBG显像鉴别路易体病与非路易体病的敏感度47-100%、特异度71-100%。

关键数值与推荐

  • 预测向痴呆进展的准确性:[18F]FDG-PET敏感度43-100%、特异度63-94%;淀粉样蛋白PET敏感度64-94%、特异度48-93%。
  • 路易体病与非路易体病鉴别:DaT-SPECT敏感度47-100%、特异度71-100%;[123I]-MIBG显像敏感度47-100%、特异度71-100%。
  • 路易体痴呆与后皮质萎缩鉴别:tau-PET敏感度88%、特异度100%。
  • 非AD疾病及tau-PET、DaT-SPECT、[123I]-MIBG显像缺乏纵向研究,准确性数据来自样本量n>20(含轻度痴呆阶段)的横断面研究作为替代结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非AD疾病(路易体痴呆和额颞叶变性)以及tau-PET、DaT-SPECT、[123I]-MIBG显像缺乏纵向研究,准确性数据来自小样本横断面研究作为替代结局。
  • 非AD疾病的纵向研究稀少,需要在这些领域额外努力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Epidemiological and logistical reasons are slowing the clinical validation of the molecular imaging biomarkers in the initial stages of neurocognitive disorders. We provide an updated systematic review of the recent advances (2017-2022), highlighting methodological shortcomings. METHODS: Studies reporting the diagnostic accuracy values of the molecular imaging techniques (i.e., amyloid-, tau-, [18F]FDG-PETs, DaT-SPECT, and cardiac [123I]-MIBG scintigraphy) in predicting progression from mild cognitive impairment (MCI) to dementia were selected according to the Preferred Reporting Items for a Systematic Review and Meta-Analysis (PRISMA) method and evaluated with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Main eligibility criteria were as follows: (1) ≥ 50 subjects with MCI, (2) follow-up ≥ 3 years, (3) gold standard: progression to dementia or diagnosis on pathology, and (4) measures of prospective accuracy. RESULTS: Sensitivity (SE) and specificity (SP) in predicting progression to dementia, mainly to Alzheimer's dementia were 43-100% and 63-94% for [18F]FDG-PET and 64-94% and 48-93% for amyloid-PET. Longitudinal studies were lacking for less common disorders (Dementia with Lewy bodies-DLB and Frontotemporal lobe degeneration-FTLD) and for tau-PET, DaT-SPECT, and [123I]-MIBG scintigraphy. Therefore, the accuracy values from cross-sectional studies in a smaller sample of subjects (n > 20, also including mild dementia stage) were chosen as surrogate outcomes. DaT-SPECT showed 47-100% SE and 71-100% SP in differentiating Lewy body disease (LBD) from non-LBD conditions; tau-PET: 88% SE and 100% SP in differentiating DLB from Posterior Cortical Atrophy. [123I]-MIBG scintigraphy differentiated LBD from non-LBD conditions with 47-100% SE and 71-100% SP. CONCLUSION: Molecular imaging has a moderate-to-good accuracy in predicting the progression of MCI to Alzheimer's dementia. Longitudinal studies are sparse in non-AD conditions, requiring additional efforts in these settings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cotta Ramusino M, Massa F, Festari C, et al. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review. Eur J Nucl Med Mol Imaging. 2024. PMID: 38355740. doi:10.1007/s00259-024-06631-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。